Finnhub•2026-04-20
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8: 00 a.m. ETFULC — Fulcrum Therapeutics Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
$7.53-45.43%Market cap535.47M
- Latest Close
- $7.53
- 30-Day Move
- -45.4%
- Market Cap
- $535M
- Shares Outstanding
- 66,600,000
- P/B Ratio
- 2.14
- ROE
- -21.5%
Analyst consensus: Buy · 16 analysts
NASDAQ:FULCPharmaceuticals / PharmaceuticalsDelayed public snapshot
Fulcrum Therapeutics Inc
A read-only Alphactor snapshot forFulcrum Therapeutics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$7.53
30-Day Move
-45.4%
Market Cap
$535M
Shares Outstanding
66,600,000
P/B Ratio
2.14
ROE
-21.5%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$7.53
-45.4%last 90 delayed daily bars
Market cap$535M
90D High
$15.32
90D Low
$6.47
Avg Volume
1,063,900
What stands out
Net margin is 8.1%, useful for comparing FULC against peers in Pharmaceuticals.
FULC is down 45.4% over the last 30 trading days shown on this page.
Latest operating income is $-23M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Rule of 40
2748.9%
Dark Pool Short %
46.9%
Fundamentals snapshot
Latest Close
$7.53
30-Day Move
-45.4%
Market Cap
$535M
Shares Outstanding
66,600,000
P/B Ratio
2.14
ROE
-21.5%
ROA
-20.4%
Operating Margin
-3.6%
Net Margin
8.1%
Debt / Equity
0
Current Ratio
27.4
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-23M
Net Income
$-20M
Gross Margin
--
Net Margin
813.0%
Current Ratio
27.40
Debt / Equity
0.00
Quality snapshot
Altman Z
16.68
Safe
Piotroski
3
Weak (0-3)
Cash Conversion
0.80x
Rule of 40
2748.9%
Elite
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $6M | $-112M | $-110M | $-99M |
| 2023-12-31 | $3M | $-111M | $-97M | $-91M |
| 2024-12-31 | $80M | $-20M | $-10M | $-2M |
| 2025-12-31 | $0 | $-85M | $-75M | $-60M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$0
Sell Value
$59M
Buys
0
Sells
9
Buy Value
$0
Sell Value
$59M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-02 | Oltmans Curtis Gale | A | 170,000 | $0.00 |
| 2026-02-02 | Tourangeau Greg | A | 57,000 | $0.00 |
| 2026-02-02 | Sapir Alex | A | 650,000 | $0.00 |
| 2026-02-02 | Gould Robert J | Sell | 15,000 | $10.72 |
| 2026-02-02 | Musso Alan A | A | 170,000 | $0.00 |
| 2026-01-02 | Gould Robert J | Sell | 15,000 | $10.87 |
| 2026-01-02 | Gould Robert J | Sell | 15,000 | $11.87 |
| 2025-12-15 | Oltmans Curtis Gale | Sell | 3,452 | $12.92 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2,074,332 | 0.03% | 2025-12-31 |
| abrdn Life Sciences Investors | 1,254,027 | 0.02% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 1,055,808 | 0.02% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 519,972 | 0.01% | 2025-12-31 |
| iShares Trust-iShares Biotechnology ETF | 438,770 | 0.01% | 2026-02-28 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 418,073 | 0.01% | 2026-01-31 |
| SPDR SERIES TRUST-State Street SPDR S&P Pharmaceuticals ETF | 367,717 | 0.01% | 2026-03-31 |
| iShares Trust-iShares Russell 2000 Value ETF | 337,781 | 0.01% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Vanguard Group
Filed 2026-01-29
$40M
+18.7%
BlackRock
Filed 2024-08-13
$30M
--
D.E. Shaw
Filed 2026-02-17
$22M
+32.0%
Citadel Advisors
Filed 2026-02-17
$14M
--
Geode Capital Management
Filed 2026-02-09
$13M
+10.1%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4.06
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
16
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.